
    
      Following a Serious Adverse Event (potential Hy's Law case), a risk-benefit assessment review
      of all preliminary safety data, and a review by Pfizer's internal hepatic injury advisory
      panel, it was concluded that PF-04287881 had an unacceptable therapeutic window. The FDA was
      notified of our intention to discontinue development as of 09April2010.
    
  